471A Stock Overview
A biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
aTyr Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.94 |
| 52 Week High | US$3.50 |
| 52 Week Low | US$1.05 |
| Beta | 1.1 |
| 11 Month Change | -8.70% |
| 3 Month Change | 79.27% |
| 1 Year Change | 162.50% |
| 33 Year Change | -57.39% |
| 5 Year Change | -31.31% |
| Change since IPO | -92.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| 471A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.5% | 0.8% | 0.8% |
| 1Y | 162.5% | -18.3% | 8.6% |
Return vs Industry: 471A exceeded the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: 471A exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| 471A volatility | |
|---|---|
| 471A Average Weekly Movement | 15.2% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 471A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 471A's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 58 | Sanjay Shukla | www.atyrpharma.com |
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders.
aTyr Pharma, Inc. Fundamentals Summary
| 471A fundamental statistics | |
|---|---|
| Market cap | €249.98m |
| Earnings (TTM) | -€60.91m |
| Revenue (TTM) | €224.31k |
1,175x
P/S Ratio-4.3x
P/E RatioIs 471A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 471A income statement (TTM) | |
|---|---|
| Revenue | US$235.00k |
| Cost of Revenue | US$54.90m |
| Gross Profit | -US$54.66m |
| Other Expenses | US$9.15m |
| Earnings | -US$63.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | -23,261.28% |
| Net Profit Margin | -27,155.74% |
| Debt/Equity Ratio | 0% |
How did 471A perform over the long term?
See historical performance and comparison